Ezogabine, clobazam, and perampanel are among the newest antiseizure drugs approved by the Food and Drug Administration between 2011 and 2012. Ezogabine and perampanel are approved for adjunctive treatment of partial epilepsy. Perampanel is also approved for adjunctive treatment of primary generalized tonic–clonic seizures. Ezogabine and perampanel have novel mechanisms of action. Ezogabine binds to voltage-gated potassium channels and increases the M-current thereby causing membrane hyperpolarization. Perampanel is a selective, non-competitive 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid receptor antagonist, which reduces neuronal excitation. Clobazam has been used worldwide since the 1970s and is approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. Clobazam is the only 1,5-benzodiazepine currently in clinical use, which is less sedating than the commonly used 1,4-benzodiazepines. Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated efficacy and good tolerability of these 3 new antiepileptic drugs. These drugs represent a welcome addition to the armamentarium of practitioners, but it remains to be seen how they will affect the landscape of pharmacoresistant epilepsy.
HauserWA, AnnegersJF, KurlandLT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia1991;32:429–45.
2.
ReynoldsEH. The ILAE/IBE/WHO Global Campaign against epilepsy: bringing epilepsy “Out of the Shadows”. Epilepsy Behav2000;1:S3–8.
3.
KarakisI, ColeAJ, MontourisGD, . Caregiver burden in epilepsy: determinants and impact. Epilepsy Res Treat2014;2014:808421. doi:10.1155/2014/808421808421
4.
BegleyCE, DurginTL. The direct cost of epilepsy in the United States: a systematic review of estimates. Epilepsia2015;56:1376–87. doi:10.1111/epi.13084
KwanP, BrodieMJ. Early identification of refractory epilepsy. N Engl J Med2000;342:314–19.
7.
SchillerY, NajjarY. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology2008;70:54–65. doi:10.1212/01.wnl.0000286959.22040.6e
BialerM, JohannessenSI, LevyRH, . Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res2009;83:1–43. doi:10.1016/j.eplepsyres.2008.09.005
11.
BialerM, JohannessenSI, KupferbergHJ, . Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res1999;34:1–41.
12.
WuttkeTV, SeebohmG, BailS, . The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol2005;67:1009–17.
OttoJF, KimballMM, WilcoxKS. Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol Pharmacol2002;61:921–7.
15.
FerronGM, PaulJ, FruncilloR, . Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol2002;42:175–82.
16.
HempelR, SchupkeH, McNeillyPJ, . Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos1999;27:613–22.
17.
TompsonDJ, CreanCS. The interaction potential of retigabine (ezogabine) with other antiepileptic drugs. Curr Clin Pharmacol2014;9:148–56.
HermannR, KnebelNG, NiebchG, . Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol2003;58:795–802.
20.
CreanCS, TompsonDJ. The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine). Clin Ther2013;35:87–93. doi:10.1016/j.clinthera.2012.12.003
21.
PatsalosPN, BerryDJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother2012;13:699–715. doi:10.1517/14656566.2012.667803
22.
HermannR, FerronGM, ErbK, . Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther2003;73:61–70.
23.
TompsonDJ, BuraglioM, BullmanJ, . Effect of hemodialysis on pharmacokinetics of ezogabine/retigabine and its N-acetyl metabolite in patients with end stage renal disease. Curr Clin Pharmacol2014;9:319–25.
24.
TompsonDJ, CreanCS. Clinical pharmacokinetics of retigabine/ezogabine. Curr Clin Pharmacol2013;8:319–31.
25.
PorterRJ, PartiotA, SachdeoR, , 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology2007;68:1197–204.
26.
BitonV, Gil-NagelA, BrodieMJ, . Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures. Epilepsy Res2013;107:138–45. doi:10.1016/j.eplepsyres.2013.08.021
27.
FrenchJA, Abou-KhalilBW, LeroyRF, . Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology2011;76:1555–63. doi:10.1212/WNL.0b013e3182194bd3
28.
BrodieMJ, LercheH, Gil-NagelA, . Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology2010;75:1817–24. doi:10.1212/WNL.0b013e3181fd6170
29.
BrodieMJ, FrenchJA, McDonaldSA, . Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: evaluation of efficacy and tolerability. Epilepsy Res2014;108:989–94. doi:10.1016/j.eplepsyres.2014.03.008
30.
LercheH, DanilukJ, LotayN, . Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Seizure2015;30:93–100. doi:10.1016/j.seizure.2015.06.002
31.
KristianB, WachtmeisterK, StefanF, . Retigabine as add-on treatment of refractory epilepsy—a cost-utility study in a Swedish setting. Acta Neurol Scand2013;127:419–26. doi:10.1111/ane.12077
32.
WehnerT, ChinnasamiS, NovyJ, . Long term retention of retigabine in a cohort of people with drug resistant epilepsy. Seizure2014;23:878–81. doi:10.1016/j.seizure.2014.08.001
33.
NiemeijerMN, van den BergME, EijgelsheimM, . Pharmacogenetics of drug-induced QT interval prolongation: an update. Drug Saf2015;38:855–67. doi:10.1007/s40264-015-0316-6
34.
AfeliSA, MalyszJ, PetkovGV. Molecular expression and pharmacological evidence for a functional role of kv7 channel subtypes in Guinea pig urinary bladder smooth muscle. PLoS One2013;8:e75875. doi:10.1371/journal.pone.0075875
35.
BrickelN, GandhiP, VanLandinghamK, . The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia2012;53:606–12. doi:10.1111/j.1528-1167.2012.03441.x
AmabileCM, VasudevanA. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy2013;33:187–94. doi:10.1002/phar.1185
38.
SankarR. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs2012;26:229–44. doi:10.2165/11599020-000000000-00000
39.
RissJ, CloydJ, GatesJ, . Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand2008;118:69–86. doi:10.1111/j.1600-0404.2008.01004.x
40.
LeahyJT, Chu-ShoreCJ, FisherJL. Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome. Neuropsychiatr Dis Treat2011;7:673–81. doi:10.2147/NDT.S20173
41.
GiraudC, TranA, ReyE, . In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos2004;32:1279–86.
42.
HashiS, YanoI, ShibataM, . Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. Eur J Clin Pharmacol2015;71:51–8. doi:10.1007/s00228-014-1773-z
43.
SeoT, NagataR, IshitsuT, . Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics2008;9:527–37. doi:10.2217/14622416.9.5.527
44.
ThomasRJ. Seizures and epilepsy in the elderly. Arch Intern Med1997;157:605–17.
MacKinnonGL, ParkerWA. Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse1982;9:19–33.
47.
WhelessJW, PhelpsSJ. Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes. J Child Neurol2013;28:219–29. doi:10.1177/0883073812463609
48.
GedzelmanER, MeadorKJ. Neurological and psychiatric sequelae of developmental exposure to antiepileptic drugs. Front Neurol2012;3:182. doi:10.3389/fneur.2012.00182
49.
PennellPB, KleinAM, BrowningN, . Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav2012;24:449–56. doi:10.1016/j.yebeh.2012.05.010
50.
Bar-OzB, NulmanI, KorenG, . Anticonvulsants and breast feeding: a critical review. Paediatr Drugs2000;2:113–26.
51.
MunnR, FarrellK. Open study of clobazam in refractory epilepsy. Pediatr Neurol1993;9:465–9.
52.
FarrellK. Benzodiazepines in the treatment of children with epilepsy. Epilepsia1986;27(Suppl 1):S45–52.
53.
JanMM, ShaabatAO. Clobazam for the treatment of intractable childhood epilepsy. Saudi Med J2000;21:622–4.
54.
SugaiK. Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia2004;45(Suppl 8):20–5. doi:10.1111/j.0013-9580.2004.458005.x
55.
KalraV, SethR, MishraD, . Clobazam in refractory childhood epilepsy. Indian J Pediatr2010;77:263–6. doi:10.1007/s12098-010-0035-z
ConryJA, NgYT, PaolicchiJM, . Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia2009;50:1158–66. doi:10.1111/j.1528-1167.2008.01935.x
58.
NgYT, ConryJA, DrummondR, . Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77:1473–81. doi:10.1212/WNL.0b013e318232de76
59.
NgYT, ConryJ, PaolicchiJ, . Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav2012;25:687–94. doi:10.1016/j.yebeh.2012.09.039
60.
NgYT, ConryJ, MitchellWG, . Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: post hoc analyses of short- and long-term clinical trial results. Epilepsy Behav2015;46:221–6. doi:10.1016/j.yebeh.2015.01.037
61.
WhelessJW, IsojarviJ, LeeD, . Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience. Epilepsy Behav2014;41:47–52. doi:10.1016/j.yebeh.2014.09.019
62.
ConryJA, NgYT, KernitskyL, , OV-1004 Study Investigators. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia2014;55:558–67. doi:10.1111/epi.12561
63.
CramerJA, SapinC, FrançoisC. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand2013;128:91–9. doi:10.1111/ane.12086
64.
ClementsKM, SkornickiM, O'SullivanAK. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav2013;29:184–9. doi:10.1016/j.yebeh.2013.07.011
65.
ShimizuH, KawasakiJ, YuasaS, . Use of clobazam for the treatment of refractory complex partial seizures. Seizure2003;12:282–6.
66.
[No authors listed]. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia1998;39:952–9.
67.
AryaR, AnandV, GargSK, . Clobazam monotherapy for partial-onset or generalized-onset seizures. Cochrane Database Syst Rev2014;10:CD009258. doi:10.1002/14651858.CD009258.pub2
68.
SchmidtD, RohdeM, WolfP, . Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol1986;43:824–6.
69.
CormanC, GubermanA, BenaventeO. Clobazam in partial status epilepticus. Seizure1998;7:243–7.
70.
SivakumarS, IbrahimM, ParkerDJr, . Clobazam: an effective add-on therapy in refractory status epilepticus. Epilepsia2015;56:e83–9. doi:10.1111/epi.13013
71.
KoeppenD, BaruzziA, CapozzaM, . Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia1987;28:495–506.
72.
MulaM, KannerAM, SchmitzB, . Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia2013;54:199–203. doi:10.1111/j.1528-1167.2012.03688.x
73.
TolbertD, HarrisSI, BekerskyI, . Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome. Epilepsy Behav2014;37:11–15. doi:10.1016/j.yebeh.2014.05.016
74.
ShihJJ, TatumWO, RudzinskiLA. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Ther Clin Risk Manage2013;9:285–93. doi:10.2147/TCRM.S37317
75.
HanadaT, HashizumeY, TokuharaN, . Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia2011;52:1331–40. doi:10.1111/j.1528-1167.2011.03109.x
76.
RogawskiMA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr2011;11:56–63. doi:10.5698/1535-7511-11.2.56
77.
CeolinL, BortolottoZA, BannisterN, . A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int2012;61:517–22. doi:10.1016/j.neuint.2012.02.035
KraussGL, PeruccaE, Ben-MenachemE, . Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia2013;54:126–34. doi:10.1111/j.1528-1167.2012.03648.x
80.
KraussGL, BarM, BitonV, . Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand2012;125:8–15. doi:10.1111/j.1600-0404.2011.01588.x
81.
FrenchJA, KraussGL, BitonV, . Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology2012;79:589–96. doi:10.1212/WNL.0b013e3182635735
82.
FrenchJA, KraussGL, SteinhoffBJ, . Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia2013;54:117–25. doi:10.1111/j.1528-1167.2012.03638.x
83.
KraussGL, SerratosaJM, VillanuevaV, . Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology2012;78:1408–15. doi:10.1212/WNL.0b013e318254473a
84.
SteinhoffBJ, Ben-MenachemE, RyvlinP, . Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia2013;54:1481–9. doi:10.1111/epi.12212
85.
KwanP, BrodieMJ, LaurenzaA, . Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes. Epilepsy Res2015;117:117–24. doi:10.1016/j.eplepsyres.2015.09.002
86.
RheimsS, RyvlinP. Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatr Dis Treat2013;9:629–37. doi:10.2147/NDT.S30129
87.
KramerLD, SatlinA, KraussGL, . Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia2014;55:423–31. doi:10.1111/epi.12527
88.
VazquezB, YangH, WilliamsB, . Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures. Epilepsia2015;56:e90–4. doi:10.1111/epi.13019
89.
LeppikIE, WechslerRT, WilliamsB, . Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res2015;110:216–20. doi:10.1016/j.eplepsyres.2014.11.015
90.
RosenfeldW, ConryJ, LagaeL, . Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol2015;19:435–45. doi:10.1016/j.ejpn.2015.02.008
91.
RektorI, KraussGL, BarM, . Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand2012;126:263–9. doi:10.1111/ane.12001
92.
MontourisG, YangH, WilliamsB, . Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel. Epilepsy Res2015;114:131–40. doi:10.1016/j.eplepsyres.2015.04.011
93.
KraussGL, PeruccaE, Ben-MenachemE, . Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia2014;55:1058–68. doi:10.1111/epi.12643
94.
FrenchJA, KraussGL, WechslerRT, . Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology2015;85:950–7. doi:10.1212/WNL.0000000000001930
95.
BiróA, StephaniU, TaralloT, . Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics2015;46:110–16. doi:10.1055/s-0035-1546276
96.
RohracherA, HöflerJ, KalssG, . Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav2015;49:354–8. doi:10.1016/j.yebeh.2015.04.005
97.
SerratosaJM, VillanuevaV, KerlingF, . Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl2013(197):30–5. doi:10.1111/ane.12102
98.
YangH, LaurenzaA, WilliamsB, . Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Epilepsy Res2015;114:122–30. doi:10.1016/j.eplepsyres.2015.04.010
99.
KoD, YangH, WilliamsB, . Perampanel in the treatment of partial seizures: time to onset and duration of most common adverse events from pooled Phase III and extension studies. Epilepsy Behav2015;48:45–52. doi:10.1016/j.yebeh.2015.05.020
100.
ZaccaraG, GiovannelliF, CincottaM, . The adverse event profile of perampanel: meta-analysis of randomized controlled trials. Eur J Neurol2013;20:1204–11. doi:10.1111/ene.12170
101.
Schulze-BonhageA, HintzM. Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability. Patient Prefer Adherence2015;9:1143–51. doi:10.2147/PPA.S63951
102.
SirvenJI. Perampanel: getting AMPed for AMPA targets. Epilepsy Curr2012;12:241–2. doi:10.5698/1535-7511-12.6.241
ZaccaraG, GiovannelliF, CincottaM, . AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel. Expert Rev Neurother2013;13:647–55. doi:10.1586/ern.13.46
106.
RöscheJ, KampfC, BeneckeR. Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus. Acta Neurol Belg2014;114:243–4. doi:10.1007/s13760-013-0225-3
107.
ZaccaraG, SchmidtD. Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development. Pharmacol Res2016;104:38–48. doi:10.1016/j.phrs.2015.12.011
108.
LeeSK. Old versus new: why do we need new antiepileptic drugs?J Epilepsy Res2014;4:39–44.
LasońW, ChlebickaM, RejdakK. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep2013;65:787–801.
111.
FrancoV, FrenchJA, PeruccaE. Challenges in the clinical development of new antiepileptic drugs. Pharmacol Res2016;103:95–104. doi:10.1016/j.phrs.2015.11.007
